

# Clinical trials of angiogenesis inhibitors for advanced breast cancer (metastatic) in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 combination with CT

Trial	Treatments	Patients	Trials design and methods
<b>sorafenib + capecitabine vs capecitabine alone</b>			
RESILIENCE , 2013 <i>ongoing</i> n=NA follow-up:	-	advanced HER2-negative breast cancer	
<b>sorafenib + gemcitabine or capecitabine vs gemcitabine or capecitabine alone</b>			
Schwartzberg , 2013 [NCT00493636] n=NA follow-up:	sorafenib (400 mg, twice daily) versus placebo	patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab	Parallel groups double-blind

## References

### RESILIENCE, 2013:

Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ, A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. *Trials* 2013;14:228. [[23876062](#)] [10.1186/1745-6215-14-228](#)

### Schwartzberg, 2013:

Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA, Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. *Clin Cancer Res* 2013;19:2745-54. [[23444220](#)] [10.1158/1078-0432.CCR-12-3177](#)

## 2 combination with CT (without taxanes)

Trial	Treatments	Patients	Trials design and methods
<b>bevacizumab + capecitabine vs capecitabine</b>			
AVF2119g (Miller) cape , 2005 n=232/230 follow-up:	capecitabine + bevacizumab 15 mg/kg iv every 3 weeks versus capecitabine (2,500 mg/m <sup>2</sup> /d) twice daily on day 1 through 14 every 3 weeks	patients with metastatic breast cancer previously treated with an anthracycline and a taxane	Parallel groups open US

continued...

Trial	Treatments	Patients	Trials design and methods
<b>RIBBON-I (Robert) on top capecitabine , 2009</b> n=NA follow-up:	Capecitabine + bevacizumab 15 mg/kg iv every 3 weeks versus capecitabine (Cape; 2,000 mg/m(2) for 14 days),	irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer	double-blind
<b>bevacizumav + CT vs CT alone</b>			
<b>RIBBON-2 (Brufsky) , 2009</b> n=NA follow-up:	addition of BV to chemotherapies used as second-line treatment for MBC versus chemo+placebo	second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer	Parallel groups open 19 countries
<b>bevacizumab + methotrexate vs methotrexate</b>			
<b>Burstein , 2005</b> n=NA follow-up:	-	-	

## References

### AVF2119g (Miller) cape, 2005:

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9 [15681523] 10.1200/JCO.2005.05.098

### RIBBON-I (Robert) on top capecitabine, 2009:

Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley E, Zhou X, Phan S RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer J Clin Oncol 2009;27:15s (abstr 1005)

Robert NJ, Diras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60 [21383283]

### RIBBON-2 (Brufsky), 2009:

Brufsky A, Rivera RR, Hurvitz SA, et al: Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for secondline treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC) J Clin Oncol 28: 119s, 2010 (abstr 1021)

Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29:4286-93 [21990397]

### Burstein, 2005:

Burstein HJ, Spigel D, Kindsvogel K, Parker LM, Bunnell CA, Partridge AH, Come SE, Ryan PD, Gelman R, Winer EP Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study Breast Cancer Res Treat 2005;94(Suppl 1):S6

Burstein HJ, Spigel D, Kindsvogel K, Parker LM, Bunnell CA, Partridge AH, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Research and Treatment 2005;94(Supplementary 1):S6.

Burstein HJ, Spigel D, Kindsvogel K, Parker LM, Bunnell CA, Partridge AH, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Research and Treatment 2005;94(Supplementary 1):S6.

Burstein HJ, Spigel D, Kindsvogel K, Parker LM, Bunnell CA, Partridge AH, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Research and Treatment 2005;94(Supplementary 1):S6.

### 3 combination with ET

Trial	Treatments	Patients	Trials design and methods
<b>bevacizumab + endocrine therapy vs endocrine therapy</b>			
LEA n=NA follow-up:	bevacizumab + letrozole/fulvestrant versus letrozole or fulvestrant	first-line therapy in postmenopausal patients with human epidermal growth factor receptor 2 (HER2) -negative and hormone receptor-positive advanced breast cancer	
<b>cediranib + fulvestrant vs fulvestrant</b>			
Hyams [NCT00454805] n=NA follow-up:	-	-	
<b>enzastaurin + fulvestrant vs Fulvestrant</b>			
De Jong n=NA	-	-	
<b>Letrozole plus bevacizumab vs letrozole</b>			
Dickler (CALGB 40503 , 2015 n=NA	-	-	

### References

#### LEA, :

Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muoz M, Garcia-Saenz J, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba-Rodriguez JR Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 2015;33:1045-52 [25691671]

#### Hyams, :

Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh MW, Alencar VM, Lombard J, Mookerjee B, Xu J, Brown K, Klein P Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs 2013;31:1345-54 [23801303]

#### De Jong, :

De Jong RS, Sonke GS, Maass N et al. Fulvestrant (FUL)plus enzastaurin (ENZA) vs FUL plus placebo (PBO) in aromatase inhibitor (AI)-resistant metastatic breast cancer(MBC): a randomized, double-blind, phase 2 trial. AnnOncol2012; 23: ix124.

#### Dickler (CALGB 40503, 2015:

Dickler M, Barry WT, Cirrincione C, Ellis MJ, Moynahan ME, Innocenti F. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). J Clin Oncol 2015;33 (suppl; abstr 501).

### 4 combination with taxanes

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>bevacizumab + docetaxel vs docetaxel</b>			
AVADO (Miles) 7.5mg , 2010 n=248/241 follow-up:	bevacizumab 7.5mg/kg every 3 weeks plus docetaxel versus placebo plus docetaxel	first-line treatment of HER2-negative metastatic breast cancer	double-blind
AVADO (Miles) 15mg , 2009 n=NA follow-up:	-	first-line treatment of HER2-negative metastatic breast cancer	
<b>bevacizumab + paclitaxel vs paclitaxel</b>			
Martin bevacizumab , 2011 n=NA follow-up:	bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle versus control	patients with HER2-negative locally recurrent or metastatic breast cancer	open design
<b>motesanib + paclitaxel vs paclitaxel</b>			
Martin (motesanib) , 2011 [NCT00356681] n=91/94 follow-up:	motesanib 125 mg orally once per da versus placebo	patients with untreated HER2-negative metastatic breast cancer	double-blind
<b>sorafenib + paclitaxel vs paclitaxel alone</b>			
Gradishar , 2013 n=NA follow-up:	paclitaxel (90mg/m <sup>2</sup> ), weekly, intravenously, 3 weeks on/1 week off) plus sorafenib (400mg, orally, twice daily) versus paclitaxel (90mg/m <sup>2</sup> ), weekly, intravenously, 3 weeks on/1 week off)	first-line therapy in patients with HER2-negative advanced breast cancer	Parallel groups double-blind
<b>bevacizumab + taxanes vs taxanes</b>			
E2100 (Miller) , 2007 [NCT00028990] n=368/354 follow-up:	paclitaxel + bevacizumab 10 mg/kg iv every 2 weeks versus paclitaxel 90 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks	patients with metastatic breast cancer not previously treated	Parallel groups open
RIBBON-I (Robert) on top Tax or anthra , 2009 n=NA follow-up:	Taxanes or anthracyclines + bevacizumab 15 mg/kg iv every 3 weeks versus taxane (Tax) -based (nab-paclitaxel 260 mg/m <sup>2</sup> ), docetaxel 75 or 100 mg/m <sup>2</sup> ), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, o	irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer	

## References

AVADO (Miles) 7.5mg, 2010:

Miles DW, Chan A, Dirix LY, Corts J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* 2010;28:3239-47 [20498403] [10.1200/JCO.2008.21.6457](https://doi.org/10.1200/JCO.2008.21.6457)

**AVADO (Miles) 15mg , 2009:**

Pivot X, Verma S, Thomssen C, Passos-Coelho JL, Latini L, Ciruelos E, Silva M, von Moos R, Chang H, Miles DW Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or Metastatic breast cancer. *J Clin Oncol* 2009;27:15s (abstr 1094)

Miles DW, Chan A, Dirix LY, Corts J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* 2010;28:3239-47 [20498403]

**Martin bevacizumab, 2011:**

Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiello-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroos R, Hurvitz S, Baos A, Adewoye H, Hei Y Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Oncol* 2011;12:369-76 [21429799] [10.1016/S1470-2045\(11\)70037-7](https://doi.org/10.1016/S1470-2045(11)70037-7)

**Martin (motesanib), 2011:**

Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiello-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroos R, Hurvitz S, Baos A, Adewoye H, Hei Y Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. *Lancet Oncol* 2011;12:369-76 [21429799] [10.1016/S1470-2045\(11\)70037-7](https://doi.org/10.1016/S1470-2045(11)70037-7)

**Gradishar, 2013:**

Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L, A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. *Eur J Cancer* 2013;49:312-22. [22954665] [10.1016/j.ejca.2012.08.005](https://doi.org/10.1016/j.ejca.2012.08.005)

**E2100 (Miller), 2007:**

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357:2666-76 [18160686] [10.1056/NEJMoa072113](https://doi.org/10.1056/NEJMoa072113)

Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. *J Clin Oncol* 2009;27:4966-72 [19720913] [10.1200/JCO.2008.21.6630](https://doi.org/10.1200/JCO.2008.21.6630)

**RIBBON-I (Robert) on top Tax or anthra, 2009:**

Robert NJ, Diras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. *J Clin Oncol* 2011;29:1252-60 [21383283]

## 5 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.